The rate of vaccination depends on the rate of vaccine development and production, and also on a smooth vaccination roll-out. COVAX has invested more than €1 000 million in research and development of new vaccines. This also includes a market place managed by CEPI, that has helped address bottlenecks in the production of the some 200 components required to produce a vaccine.
Major vaccine exporters
Categories:
European Parliamentary Research Service
Related Articles
We write about
Disclaimer and Copyright statement
The content of all documents (and articles) contained in this blog is the sole responsibility of the author and any opinions expressed therein do not necessarily represent the official position of the European Parliament. It is addressed to the Members and staff of the EP for their parliamentary work. Reproduction and translation for non-commercial purposes are authorised, provided the source is acknowledged and the European Parliament is given prior notice and sent a copy.
For a comprehensive description of our cookie and data protection policies, please visit Terms and Conditions page.
Copyright © European Union, 2014-2025. All rights reserved.




Be the first to write a comment.